

RECEIVED
CENTRAL FAX CENTERThe Offices of
HENRY M. FEIEREISEN

Patent Agent

350 Fifth Avenue, Suite 4714, New York, N.Y. 10118
Tel: (212) 244-5500, Fax: (212) 244-2233, E-Mail: info@feiereisenllc.com

OCT 03 2005

FACSIMILE TRANSMISSION

TO:	Commissioner for Patents Alexandria, VA 22313-1450
ATTENTION:	Examiner: David H. Willse, Group Art Unit: 3738
FAX-NO.:	(571) 273-8300
FROM:	Ursula B. Day, Reg. No.: 47,296
APPL. NO.	10/601,280
FILED:	June 20, 2003
DOCKET NO:	MÜCKTER-2
TYPE OF PAPER:	RESPONSE TO OFFICIAL ACTION dated July 1, 2005
DATE:	October 3, 2005
NO. OF PAGES (including this page):	15 pages
MESSAGE:	DELIVER DIRECTLY TO EXAMINER

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the U.S. Patent and Trademark Office, Alexandria, VA 22313-1450 on the date shown below.

Ursula B. Day

Name of Representative

SignatureOct. 3, 2005

Date

The information contained in this facsimile message is confidential information intended only for the use of the individual or entity named above. If the reader of this message is not the intended recipient, this serves as notice that any dissemination, distribution or copying of the communication is strictly prohibited. If this communication is received in error, please notify sender at above telephone number.

OCT 03 2005

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Docket No.: MÜCKTER-2

In re Application of:	}
HELMUT MÜCKTER) Examiner: Willse, David H
Appl. No.: 10/601,280) Group Art Unit: 3738
Filed: June 20, 2003)
For: BLOOD PUMP WITH IMPELLER)

RESPONSE TO OFFICIAL ACTION
dated July 1, 2005

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SIR:

This communication is in response to the Official Action of July 1, 2005 having a shortened period for response terminating October 1, 2005. Since that day falls on a Saturday, a response is timely filed by October 3, 2005.

The Commissioner is hereby authorized to charge any fees which may be required during the pendency of this application, including any patent application processing fees under 37 C.F.R. 1.17, and any filing fees under 37 C.F.R. 1.16, including presentation of extra claims, or credit any overpayment to Deposit Account 06-0502.

Please amend the above-entitled application as follows: